Seattle Genetics Drug Scratches Out Win In Hodgkin Lymphoma – Forbes

ForbesIn a closely watched result, Adcentris, a cancer drug sold by the biotech firm Seattle Genetics and the Japanese drug giant Takeda, outperformed traditional chemotherapy in front-line Hodgkin lymphoma, a result that is likely to lead to a broadened …Seattle Genetics, Takeda lymphoma drug succeeds late-stage trialReutersTakeda, Seattle Genetics Report Positive Results From Phase 3 […]

from WordPress http://ift.tt/2sHVlZa
via IFTTT